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von Willebrand Factor, C-Reactive Protein, and 5-Year
Mortality in Diabetic and Nondiabetic Subjects
The Hoorn Study
Agnes Jager, Victor W.M. van Hinsbergh, Piet J. Kostense, Jef J. Emeis, John S. Yudkin, Giel Nijpels,
Jacqueline M. Dekker, Robert J. Heine, Lex M. Bouter, Coen D.A. Stehouwer
Abstract—Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality
in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf
and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with
cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose
tolerance–stratified sample (n5631) of a population-based cohort aged 50 to 75 years was followed prospectively for
5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (1.56 IU/mL) and CRP
(.2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular
mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects
separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride,
smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2
to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate
analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between
vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar
among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP.
For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are
independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The
association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors.
Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP
predict mortality through different pathways.(Arterioscler Thromb Vasc Biol. 1999;19:3071-3078.)
Key Words: von Willebrand factorn C-reactive proteinn cardiovascular mortalityn non–insulin-dependent diabetes
mellitusn acute phase reactant
A ccumulating evidence indicates that endothelial dys-function and chronic low-grade inflammation play a
pivotal role in the pathogenesis of atherothrombotic
disease.1–3
Increased levels of von Willebrand factor (vWf) have been
proposed to reflect generalized endothelial dysfunction.4,5
Indeed, subjects with peripheral,6 cerebral,7 and coronary
artery atherosclerotic disease8 have increased levels of vWf
compared with control subjects. Furthermore, high levels of
vWf have been shown to predict cardiovascular mortality in
patients recently presenting with cardiovascular disease.7–11
However, 2 population-based studies showed no significant
association of high vWf levels with cardiovascular
mortality.12,13
C-reactive protein (CRP), an acute-phase reactant, is a
marker of inflammation. In healthy subjects, its concentration
is generally low, rising 5-fold to.100-fold in acute illness.
Slightly increased, but conventionally normal, CRP levels
may reflect a chronic low-grade inflammatory state and have
been found to be an independent predictor of cardiovascular
mortality among subjects at high risk of atherothrombotic
events,8,14–16as well as among healthy subjects.17–19
Levels of both vWf20,21 and CRP22 are increased in
non–insulin-dependent diabetes mellitus (NIDDM) compared
with levels in control subjects. NIDDM is associated with a 2-
to 4-fold increased cardiovascular mortality,23 but there are
few prospective data for vWf and cardiovascular disease in
NIDDM21,24 and none for CRP.
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We performed a prospective population-based cohort study
among nondiabetic and diabetic subjects to investigate the
relation between vWf and CRP concentrations on one hand
and cardiovascular and all-cause mortality on the other. A
further aim of the present study was to investigate whether
vWf and CRP affect the risk of mortality through similar
pathways. We reasoned that if vWf and CRP confer mutually
independent excess risks of mortality, this would argue in
favor of the idea that vWf and CRP affect mortality risk
through substantially different pathways.
Methods
General Study Design
The Hoorn study is a population-based cohort study of disturbances
of glucose tolerance in a white population aged 50 to 75 years
conducted from 1989 to 1992 (n52484 subjects; response rate
71%).25 An extensive investigation was performed in an age-, sex-,
and glucose tolerance–stratified random sample (n5631, response
rate 89%).25–27
From these subjects, we obtained an ankle-brachial blood pressure
index (n5631) and a resting ECG (n5625). Subjects were classified
as having (1) peripheral arterial disease (PAD) when they had an
ankle-brachial pressure index,0.9 in either leg and/or when they
had undergone a peripheral arterial bypass or amputation,28
(2) ischemic heart disease (IHD) when they had an ECG with a
Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 and/or had
undergone coronary bypass surgery or angioplasty, and (3) cerebro-
vascular disease when they had evidence of a past transient ischemic
attack or stroke according to the World Health Organization (WHO)
cardiovascular questionnaire.29
vWf and CRP
Concentrations of vWf and CRP were assessed in deep frozen
(270°C) heparin plasma samples. No plasma samples were available
for 21 subjects. vWf antigen levels were estimated in duplicate by
ELISA, essentially as described,30 with the use of polyclonal
antibodies from Dako (Glostrup, Denmark), and they were expressed
as percentage of vWf detected in pooled citrated plasma of healthy
volunteers. According to the 4th International Standard for vWf in
plasma (NIBSC code 97/586), the pooled citrated plasma contained
1.03 IU/mL of vWf antigen. CRP levels were measured in duplicate
with an enzyme immune assay that used rabbit antibodies against
CRP (Dako) as both the capture and tagging antibody, with a
sensitivity of 0.2 mg/L.31 CRP standard serum (Behring Diagnostics
GmbH) was used for calibration. In 11 subjects, the CRP level was
undetectable and therefore set at 0.2 mg/L.
Other Measurements
Data on blood pressure, weight, height, body mass index, glycated
hemoglobin, fasting specific plasma insulin, serum total cholesterol,
HDL cholesterol, and triglyceride levels were obtained.25 ABO
blood groups were determined by standard agglutination techniques
using commercial test erythrocytes. LDL cholesterol was calculated
by the Friedewald formula,32 except when the triglyceride level was
.4.55 mmol/L (n523). Hypertension was defined as diastolic
pressure$95 mm Hg, systolic pressure$160 mm Hg, and/or the use
of antihypertensive drugs.33 Current smoking was defined as cur-
rently smoking cigarettes and/or cigars.
Follow-Up
Data on the vital status of the subjects on April 1, 1997, were
collected from the mortality register of the municipality of Hoorn. Of
49 subjects who moved out of town, information on vital status was
obtained from the new local municipalities. For each subject, we
determined whether or not death had occurred in the first 5 years of
follow-up and, if so, the date at which death occurred. For all
subjects who had died, the cause of death was classified according to
the 9th edition of the International Classification of Diseases.26
Cardiovascular mortality was defined as codes 390 to 459; cancer
mortality, as codes 140 to 240. Information on cause of death could
not be obtained for 6 (10%) of the deceased subjects.
All participants gave informed consent for the present study,
which was approved by the local ethics committee.
Statistical Analyses
All analyses were performed with SPSS 7.5 for Windows 95.
Survival over 5 years of follow-up was calculated by Kaplan-Meier
curves for different groups, and differences were tested by the log
rank test. Differences between groups in continuous variables that
had a normal distribution were tested by Studentt tests; in continu-
ous variables that had a skewed distribution, by Mann-Whitney tests;
and in percentage of subjects with versus without the presence of
dichotomous variables, byx2 tests. The correlation between vWf and
log-transformed CRP was assessed with the Pearson correlation
coefficient. Predictors of 5-year cardiovascular and all-cause mor-
tality were determined by Cox proportional hazards multiple regres-
sion analysis (in all cases, because of the stratification procedure)
with adjustment for age, sex, and glucose tolerance status. Results
are described as relative risks (RRs [hazard ratios]) with 95% CIs.
Potential risk factors measured on a continuous scale were used as
such in the regression models, except for HDL cholesterol and body
mass index, because the association of these variables with all-cause
mortality was nonlinear. Therefore, a low HDL cholesterol level was
defined as a level,0.9 mmol/L34; obesity, as a body mass index
.27 kg/m2 for men and.26 kg/m2 for women.35 Levels of fasting
insulin and triglyceride were log-transformed because of a better fit
of the regression model. Subjects were grouped according to levels
of vWf and CRP. Subjects with levels in the highest tertile were
compared with those with levels in the 2 lower tertiles. vWf and CRP
were thus entered into the regression models as dichotomized
variables, ie, upper tertile versus lower tertiles. (The lowest and
middle tertiles were taken together because preliminary analyses
showed that the RRs of mortality for these 2 lower tertiles of vWf
and CRP were similar, whereas the RR for the upper tertile of vWf
and CRP was increased.) To evaluate a possible effect-modifying
role of potential risk factors with regard to cardiovascular or
all-cause mortality, Cox regression analyses were performed with the
risk factor of interest, vWf (or CRP), their product term, age, sex,
and glucose tolerance status in the model. A significant RR for the
product term was considered effect modification by that risk factor.
To assess whether the associations of vWf and CRP with mortality
were independent, regression analyses were primarily adjusted for all
risk factors that were statistically significant in initial analyses,
secondarily adjusted for the presence of cardiovascular morbidity,
and finally adjusted for other potential risk factors of interest that
showed no significant association in the initial analyses.
To investigate whether vWf and CRP affected risk of mortality
through similar pathways, regression analyses were performed that
included both vWf and CRP as independent variables. A 2-sided
probability value ofP,0.05 was considered statistically significant.
Results
Figures 1 and 2 (insets) show the distribution of vWf and
CRP. The ranges of vWf and CRP levels were 0.24 to 3.89
IU/mL and 0.2 to 35.2 mg/L, respectively. Thirty-three
(5.4%) of the subjects had a CRP level.10.0 mg/L. Table 1
shows the baseline characteristics of the study population.
Levels of vWf and CRP in the upper tertile compared with the
lower tertiles were significantly associated with higher age,
higher levels of fasting glucose, glycated hemoglobin, and
insulin, and higher body mass index, systolic blood pressure,
and prevalence of NIDDM, hypertension, and PAD. CRP
levels in the upper tertile were, in addition, significantly
associated with higher levels of triglycerides, higher waist-
to-hip ratio, and a higher prevalence of women, current
smoking status, and IHD compared with CRP levels in the
lower tertiles (data not shown).
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After 5 years of follow-up, 58 of the 631 subjects had died,
of whom 24 (41%) had died of cardiovascular disease.
Subjects who died had higher levels of vWf (mean6SD) and
CRP (median interquartile range) compared with those that
survived: 1.76 0.72 versus 1.3360.68 IU/mL and 3.33 (1.36
to 6.88) versus 1.68 (0.79 to 3.35) mg/L, respectively. Table
1 shows RRs of mortality associated with potential risk
factors.
von Willebrand Factor
In the entire group, vWf levels in the upper tertile were
associated with an'4-fold increased risk of cardiovascular
mortality (Figure 1) and, after adjustment for age, sex, and
glucose tolerance status, with an'3-fold increased risk
(Table 2). After further adjustment for hypertension, current
smoking, low level of HDL cholesterol, level of triglyceride,
IHD, and PAD, the RR associated with vWf was 3.04 (Table
2). Subgroup analyses in nondiabetic and diabetic subjects
showed that vWf was associated with a 4-fold and 2-fold
increased risk of cardiovascular death, respectively, after
correction for age, sex, and impaired glucose tolerance (Table
2). Further adjustment increased the RR associated with vWf
to 11.83 among nondiabetic subjects, whereas the RR among
diabetic subjects remained 2.51 (Table 2).
The RR of all-cause mortality associated with vWf in the
upper tertile was 2.03, which was not affected by adjustment
(Table 2).
To investigate whether the RR of vWf was similar among
different risk groups, we performed analyses with interaction
terms added (see Methods). Impaired glucose tolerance,
NIDDM, current smoking, levels of triglyceride and total
cholesterol, body mass index, IHD, and PAD showed no
significant interaction (for interaction term,P.0.2). The RRs
of cardiovascular mortality associated with vWf in the upper
tertile among women, in subjects.65 years of age, and in the
presence of hypertension or low levels of HDL cholesterol
were 12.3 (P50.03), 6.5 (P50.07), 5.0 (P50.12), and 4.5
(P50.10) times higher, respectively, than when these factors
were absent (data not shown).
The hypothesis has been advanced that the ABO blood
group could be the explanation for the association between
vWf level and cardiovascular mortality, because blood groups
are associated with both cardiovascular disease and levels of
vWf.36 The prevalences of blood groups O, A, B, and AB
were 45%, 39%, 11%, and 6%. After adjustment for age, sex,
and glucose tolerance status, blood group non-O was associ-
ated with a 2-fold increased cardiovascular mortality com-
pared with blood group O (RR 2.08 [95% CI 0.85 to 5.07]
among all subjects). Additional adjustment for risk factors
mentioned in Table 2 did not materially change this result
(data not shown). The levels of vWf were significantly lower
in blood group O compared with blood group non-O
(mean6SD 1.1660.58 and 1.4960.72 IU/mL, respectively;
P,0.05). The RRs of cardiovascular mortality associated
with vWf level and blood group non-O were not importantly
affected by mutual adjustment (eg, for model 1 in Table 2,
RRs 3.02 [1.22 to 7.53] and 1.77 [0.72 to 4.38], respectively).
Further adjustment for risk factors mentioned in Table 2 gave
similar results (data not shown). Analyses performed among
blood group O and blood group non-O separately gave
similar results (eg, for model 1 in Table 2, RRs 2.01 [0.42 to
9.51] and 3.28 [1.05 to 10.25] among all subjects,
respectively).
C-Reactive Protein
In the entire group, CRP levels in the upper tertile were
associated with an'3-fold increased risk of cardiovascular
mortality (Figure 2) and, after adjustment for age, sex, and
glucose tolerance status, with an'2-fold increased risk
(Table 3). After further adjustment for hypertension, current
smoking, low level of HDL cholesterol, triglyceride level,
IHD, and PAD, the RR associated with CRP was 1.41 (Table
3). The RRs of cardiovascular mortality associated with CRP
in the upper tertile were similar among nondiabetic and
diabetic subjects ('2-fold). After further adjustment, the RR
of CRP decreased to 0.83 among nondiabetic and to 1.34
among diabetic subjects (Table 3).
CRP was a significant predictor of all-cause mortality after
adjustment for age, sex, and glucose tolerance status in the
Figure 1. Cardiovascular survival (Kaplan-Meier method)
according to plasma vWf levels in the upper tertile (.1.56
IU/mL) vs the lower 2 tertiles. Inset shows percentage of vWf
.1.56 IU/mL per glucose tolerance status.
Figure 2. Cardiovascular survival (Kaplan-Meier method)
according to plasma CRP levels in the upper tertile (.2.84
mg/L) vs the lower 2 tertiles. Inset shows percentage of CRP
.2.84 mg/L per glucose tolerance status.
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entire group (Table 3). After adjustment for other risk factors,
the RR decreased from 1.88 to 1.33 (Table 3).
Impaired glucose tolerance, NIDDM, hypertension, current
smoking, low levels of HDL cholesterol, levels of triglyceride
and total cholesterol, body mass index, IHD, and PAD
showed no significant interaction (for interaction term,
P.0.2). The RRs of cardiovascular mortality associated with
CRP in the upper tertile among women and subjects older
than 65 years were, respectively, 3.6 (P50.18) and 6.5
(P50.13) times higher than those among men and subjects
aged,65 years (data not shown).
Additional Analyses
The correlation between vWf and log-transformed CRP in the
entire group was 0.10 (P50.014). The RRs of cardiovascular
mortality associated with vWf and CRP in their respective
upper tertiles were not importantly affected by mutual adjust-
ment (Table 4). Further adjustment also did not materially
affect the results (Table 4). vWf and CRP showed no mutual
interaction (for interaction term,P50.99).
Twenty-six (45%) of the subjects died of cancer. After
adjustment for age, sex, and glucose tolerance status, both
vWf and CRP were not significantly associated with risk of
cancer mortality (RRs 1.50 [0.67 to 3.34] and 1.23 [0.54 to
2.82], respectively).
Because the RRs of mortality were similar in the lower
tertiles of either vWf or CRP and increased in the upper tertile
only, we further investigated whether there was a threshold
value of vWf and CRP for predicting mortality by changing
the definitions of a “high” vWf and CRP concentration. When
vWf was dichotomized as with 1.22 IU/mL (median) or 1.74
IU/mL (highest quartile) as cutoffs, the risk estimates for
cardiovascular mortality were slightly lower (eg, for model 1
in Table 2, RRs 2.36 [0.93 to 5.99] and 2.63 [1.16 to 5.98]
compared with 2.80 [1.18 to 6.66], respectively). When CRP
was dichotomized with 2.11 mg/L (used in Reference 18),
3.20 mg/L (used in Reference 17), or 3.60 mg/L (used in
Reference 15) as cutoffs, the RR of cardiovascular mortality
was lower (eg, for model 1 in Table 3, RRs 1.35 [0.56 to
3.22], 1.93 [0.85 to 4.41], and 1.58 [0.68 to 3.64] compared
with 2.23 [0.95 to 5.21], respectively). Exclusion of subjects
with vWf level ,0.50 IU/mL (n539) or of subjects with CRP
level .10.0 mg/L gave similar results (data not shown).
Analyses with a shorter follow-up duration showed higher
RRs of cardiovascular mortality associated with vWf and
CRP levels in their respective upper tertiles. For example,
after adjustment for age, sex, and glucose tolerance status, the
RRs for vWf and CRP in the first 3 years of follow-up were
4.02 (1.09 to 14.93) and 4.46 (1.14 to 17.41); for 3 to 5 years
of follow-up, the values were 1.86 (0.55 to 6.37) and 1.15






Mortality According to Indicated Change of Risk Factors





Male, % 48 Yes vs no 1.62 (0.72–3.65) 1.73 (1.03–2.92)
Age, y 6467 Per 5-year increase 1.66 (1.15–2.39) 1.63 (1.29–2.06)
HbA1c, % of hemoglobin 5.961.3 Per 1% of hemoglobin increase 1.08 (0.84–1.38) 1.15 (0.98–1.34)
Fasting insulin, pmol/L 84 (63–119) Per 10% pmol/L increase* 0.99 (0.90–1.08) 1.02 (0.96–1.08)
Impaired glucose tolerance, % 27 Yes vs no 0.50 (0.10–2.47) 1.21 (0.55–2.67)
NIDDM, % 27 Yes vs no 4.19 (1.63–10.76) 3.72 (1.99–6.99)
Body mass index, kg/m2 27.264.0 Yes vs no†‡ 1.61 (0.61–4.21) 1.39 (0.76–2.51)
Total cholesterol, mmol/L 6.661.2 Per 1.0 mmol/L increase 1.30 (0.95–1.79) 1.14 (0.92–1.40)
LDL cholesterol, mmol/L 4.561.1 Per 1.0 mmol/L increase 1.31 (0.90–1.90) 1.09 (0.85–1.40)
HDL cholesterol, mmol/L 1.360.4 Yes vs no§ 4.00 (1.66–9.65) 2.38 (1.28–4.43)
Triglycerides, mmol/L 1.6 (1.2–2.2) Per 10% mmol/L increase* 1.10 (1.02–1.18) 1.07 (1.01–1.12)
Hypertension, % 39 Yes vs no 3.36 (1.29–8.76) 1.56 (0.91–2.69)
Current smokers, % 28 Yes vs no 2.35 (0.99–5.54) 2.21 (1.28–3.82)
IHD, % 15 Yes vs no\ 3.14 (1.36–7.24) 2.05 (1.16–3.64)
Peripheral arterial disease, % 11 Yes vs no¶ 3.75 (1.62–8.68) 2.06 (1.14–3.71)
Stroke, % 5 Yes vs no# Not applicable** 0.35 (0.05–2.51)
Baseline values are percentages, mean6SD, or median (interquartile range). Mortality values are RR with 95% CIs obtained with Cox regression
analyses of 5-year cardiovascular and all-cause mortality associated with continuous or dichotomous variables after adjustment for age, sex, impaired
glucose tolerance, and NIDDM, except when this was the variable under consideration. HbA1c indicates glycated hemoglobin.
*Log-transformed.
†.27 vs #27 kg/m2 for males and .26 vs #26 kg/m2 for females.
‡Associations with waist-to-hip ratio were weaker.
§,0.9 vs $0.9 mmol/L.
\Minnesota code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1 on the ECG, coronary bypass operation, and/or angioplasty.
¶Ankle-brachial pressure index ,0.90 and/or peripheral arterial bypass or amputation.
#Stroke or transient ischemic attack according to the WHO questionnaire.
**No cardiovascular deaths among subjects with previous stroke.
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(0.32 to 4.10), respectively. The difference between these risk
estimates (the first 3 years compared with 3 to 5 years of
follow-up) was not significant (P50.40 and P50.15,
respectively).
Discussion
This prospective study showed that higher levels of vWf are
associated with 5-year cardiovascular and all-cause mortality
in both diabetic and nondiabetic subjects. This association is
independent of conventional risk factors and blood groups.
The level of CRP is a predictor of all-cause mortality, which,
however, is not independent of other risk factors. Mutual
adjustment of vWf and CRP did not markedly affect the RRs
of mortality. These results, together with the weak correlation
between vWf and CRP at baseline (r50.10), argue in favor of
the idea that vWf and CRP predict mortality through different
pathways.
Our finding that vWf is an independent predictor of
cardiovascular mortality is in line with results of some7–11but
not all studies.11–13,37–39To the best of our knowledge, this is
the first study that provides evidence for an independent
association of vWf with cardiovascular mortality in the
general population. The precise mechanism by which vWf
increases cardiovascular risk is unclear. It has been suggested
that vWf is a marker of generalized endothelial dysfunc-
tion,4,5 which is an important feature of atherothrombotic
disease.1–3 Alternatively, it has been hypothesized that vWf,
as an acute-phase reactant,40 reflects endothelial activation
and stimulation (without necessarily implying endothelial
dysfunction) and, as such, is a marker of more severe disease
in general. Accordingly, the ECAT study (Juhan-Vague et
al41) showed that among subjects with angina pectoris, the
independent RR of cardiovascular mortality associated with
vWf disappeared after adjustment for variables related to
inflammation, ie, CRP and/or fibrinogen. In other words, the
risk predicted by vWf was explained by the risk predicted by
CRP and/or fibrinogen. In contrast, we found that mutual
adjustment of vWf and CRP did not materially change the
TABLE 2. Relative Risk of 5-Year Cardiovascular and All-Cause Mortality Associated With Presence of vWF Highest Tertile (>1.56














1 Age, sex, impaired glucose tolerance, and NIDDM 2.80 (1.18–6.66) 4.10 (0.96–17.54) 2.30 (0.80–6.64) 2.03 (1.19–3.47)
2 Model 1 plus hypertension, current smoking, low HDL
cholesterol level,‡ and low triglyceride level§
3.08 (1.20–7.91) 10.96 (1.57–76.71) 2.50 (0.77–8.15) 2.03 (1.16–3.55)
3 Model 2 plus IHD\ and peripheral arterial disease¶ 3.04 (1.16–7.94) 11.83 (1.59–87.87) 2.51 (0.75–8.41) 2.04 (1.16–3.61)
4 Model 3 plus obesity# and cholesterol level 2.91 (1.11–7.63) z z z z z z 1.98 (1.12–3.52)
Values are RR (95% CI) of 5-year mortality associated with vWF concentration obtained with Cox multiple regression analyses. Models are as follows: model 1,
stratification variables; model 2, as model 1, plus all risk factors significantly associated with cardiovascular mortality (shown in Table 3, left column); model 3, as
model 2, plus cardiovascular morbidity significantly associated with mortality (shown in Table 3, left column); and model 4, as model 3, plus major risk factors that
were nonsignificant (Table 3).
*No plasma samples available for 21 subjects. †RRs of mortality of vWf among subjects with normal and impaired glucose tolerance were similar; these categories
were therefore pooled in the analyses. ‡HDL cholesterol level ,0.9 mmol/L. §Log-transformed triglyceride levels. \Minnosota code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1
on ECG coronary bypass operation, and/or angioplasty. ¶Ankle-brachial pressure index ,0.90 and/or peripheral arterial bypass or amputation. #Body mass index
.27.0 vs #27.0 kg/m2 for men and .26.0 vs #26.0 kg/m2 for women.
TABLE 3. Relative Risk of 5-Year Cardiovascular and All-Cause Mortality Associated With Presence of CRP in Highest Tertile (>2.84














1 Age, sex, impaired glucose tolerance, and NIDDM 2.23 (0.95–5.21) 1.73 (0.40–7.45) 2.39 (0.80–7.13) 1.88 (1.10–3.24)
2 Model 1 plus hypertension, current smoking, low HDL
cholesterol level,‡ and low triglyceride level§
1.93 (0.81–4.63) 0.85 (0.17–4.25) 1.97 (0.62–6.27) 1.67 (0.96–2.89)
3 Model 2 plus IHD\ and peripheral arterial disease¶ 1.41 (0.57–3.50) 0.83 (0.17–4.09) 1.34 (0.41–4.43) 1.39 (0.79–2.46)
4 Model 3 plus obesity# and cholesterol level 1.32 (0.52–3.35) z z z z z z 1.33 (0.75–2.37)
Values are RR (95% CI) of 5-year mortality associated with CRP concentration obtained with Cox multiple regression analyses. Models are as described in Table 2.
*No plasma samples available for 21 subjects. †RRs of mortality of CRP among subjects with normal and impaired glucose tolerance were similar; these categories
were therefore pooled in the analyses. ‡HDL cholesterol level ,0.9 mmol/L. §Log-transformed triglyceride levels. \Minnosota code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1
on ECG, coronary bypass operation, and/or angioplasty. ¶Ankle-brachial pressure index ,0.9 and/or peripheral arterial bypass or amputation. #Body mass index
.27.0 vs #27.0 kg/m2 for men and .26.0 vs #26.0 kg/m2 for women.
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risk estimates, suggesting different mechanisms through
which vWf and CRP predict mortality. Finally, vWf plays an
important role not only in platelet adhesion and aggregation
but also in coagulation42,43 and may thus enhance the risk of
thrombogenesis. Accordingly, the increase of vWf within 48
hours after a myocardial infarction was a predictor of the rate
of restenotic cardiovascular events within 14 days, whereas
the increase of CRP, as a marker of acute-phase response, was
not.44 Our finding that the RR of mortality associated with
vWf is strongest in the first few years of follow-up is
compatible with the view that vWf is related more to
atherothrombotic than to atherosclerotic disease. In sum, our
data are consistent with the concept that a high vWf level, in
the general diabetic and nondiabetic population, is a marker
of generalized endothelial dysfunction and/or a prothrom-
botic state but not with the view that a high vWf level reflects
an acute-phase response.
Slightly increased levels of CRP have been found to be
associated with increased cardiovascular risk in subjects with
angina pectoris8,14,15and in healthy subjects.17–19 It has been
hypothesized that a chronic low-grade bacterial infection,
which can cause raised CRP levels within the normal range
and is associated with coronary heart disease,45,46 is the
mechanism through which CRP predicts cardiovascular mor-
tality.18,19 On the other hand, CRP itself has bioactive
properties that may counterregulate the inflammatory re-
sponse.46–48Nevertheless, these anti-inflammatory properties
have been found only in studies using concentrations of CRP
above the conventional normal range and may thus be less
important for slightly increased levels of CRP. We found that
high CRP levels were associated with a 2-fold increased risk
of cardiovascular mortality. This result is in partial agreement
with previous studies among apparently healthy subjects.16–19
First, in contrast to previous studies,17–19we showed that the
association of CRP with cardiovascular mortality was to a
large extent explained by other risk factors (Table 5). Second,
we found that the RR of mortality for CRP was stronger in the
first few years of follow-up, whereas Ridker et al18 found that
this risk was stable in time, at least up to 8 years of follow-up.
Third, we did not find a linear association of CRP level with
mortality, whereas others did.18,19 Fourth, although we did
find evidence for a stronger association of CRP with mortal-
ity risk among women and among subjects aged.65 years,
we could not demonstrate interactions, with regard to mor-
tality risk, between CRP and current smoking,16,49 total
cholesterol levels,50 or IHD.16 Fifth, the determinants of CRP
that we found (Table 1) were in line with some51 but not all
previous studies.17 Taken together, these data suggest that the
association between CRP and cardiovascular mortality differs
between populations. This hypothesis requires further study.
We observed similar associations of vWf and CRP with
RR of cardiovascular mortality among nondiabetic and dia-
betic subjects. NIDDM is associated with a 2- to 4-fold
increase of cardiovascular mortality.23 Various hypotheses
have been put forward to explain the mechanism through
which diabetes accelerates atherothrombosis. Potential
glucose-mediated mechanisms include increased oxidative
stress, increased concentrations of advanced glycation end
products, and activation of the diacylglycerol–protein kinase
C pathway,5,52 which can directly or indirectly induce endo-
thelial dysfunction, an acute phase response, and a procoagu-
lant state.5,52In other words, the associations of vWf and CRP
with cardiovascular mortality could be different between
diabetic and nondiabetic subjects, because the underlying
pathophysiological conditions that cause increased levels of
vWf and CRP might be dissimilar. However, from our data,
it seems that once levels of vWf and CRP are increased, their
associations with cardiovascular mortality are similar among
diabetic and nondiabetic subjects.
As has been shown previously, we found higher RRs of
mortality associated with vWf12,53among women than among
men. Furthermore, vWf was a stronger predictor in subjects
aged.65 years and in the presence of hypertension or a low
level of HDL cholesterol. We could neither prove nor
disprove the presence of interaction between vWf and these
last 3 variables; therefore, more comprehensive studies are
necessary to address these issues.
The levels of vWf and CRP were both measured once,
which may have led to nondifferential misclassification and,
therefore, an underestimation of the RRs associated with
mortality. The present study was too limited to assess, with
much precision, above what threshold vWf and CRP are
associated with mortality. Furthermore, a longer follow-up
duration is necessary to establish or exclude definitively the
TABLE 4. Relative Risk of 5-Year Cardiovascular and All-Cause Mortality Associated With Plasma Concentration of vWf and CRP in
Upper Tertile After Mutual Adjustment
Model Added Variables
RR (95% CI)









1 Age, sex, impaired glucose tolerance, NIDDM, and vWf or CRP* 2.64 (1.10–6.31) 2.04 (0.87–4.79) 1.95 (1.14–3.35) 1.79 (1.04–3.09)
2 Model 1 plus hypertension, current smoking, low HDL cholesterol
level,† low triglyceride level,‡ and vWf or CRP*
2.97 (1.15–7.66) 1.82 (0.75–4.41) 2.00 (1.14–3.50) 1.63 (0.94–2.83)
3 Model 2 plus IHD,§ peripheral arterial disease,\ and vWf or CRP* 3.00 (1.14–7.87) 1.32 (0.52–3.35) 2.03 (1.15–3.60) 1.37 (0.77–2.42)
Values are RR (95% CI) of 5-year mortality associated with vWf and CRP concentration in the upper tertile (.1.56 IU/mL and .2.84 mg/L, respectively) vs the
lower tertiles obtained with Cox multiple regression analyses. Models are as follows: model 1, stratification variables; model 2, as model 1, plus all risk factors
significantly associated with mortality (shown in Table 3, left column); model 3, as model 2, plus cardiovascular morbidity significantly associated with mortality (shown
in Table 3, left column).
*With the variable added that was not already in the model. †HDL cholesterol level ,0.9 mmol/L. ‡Log-transformed triglyceride levels. §Minnosota code 1.1–1.3,
4.1–4.3, 5.1–5.3, or 7.1 on ECG, coronary bypass operation, and/or angioplasty. \Ankle-brachial pressure index ,0.9 and/or peripheral arterial bypass or amputation.
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existence of time dependence in the associations of vWf and
CRP with mortality risk. Although our data support the
concept that levels of vWf and CRP predict cardiovascular
mortality through different pathophysiological mechanisms,
we did not investigate these possible mechanisms.
We have shown that the level of vWf is a strong indepen-
dent predictor of cardiovascular and all-cause mortality in the
general population, whereas the association of CRP with
mortality is confounded by other risk factors. The risk
estimates of cardiovascular mortality associated with vWf
and CRP were mutually independent, suggesting that vWf
and CRP predict mortality through different pathways. This,
along with our finding that the risk predicted by vWf seems
time dependent (stronger in the first few years of follow-up),
gives support to the hypothesis that vWf is more likely to be
a marker of risk for atherothrombotic than for atherosclerotic
disease. From a therapeutic point of view, this is of clinical
relevance, because antithrombotic agents have been shown to
reduce the risk of a first myocardial infarction54 and to
provide a favorable outcome after a myocardial infarction.44
Therefore, we suggest that the use of antithrombotic agents
among subjects with high vWf levels might be particularly
effective in reducing the risk of myocardial infarction. Ran-
domized clinical trials are necessary to investigate this
hypothesis.
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